| The company's consolidated net profit surged 74.60% to Rs 25.30 crore in Q4 FY26, compared with Rs 14.49 crore in the same period last year. Revenue from operations rose 35.81% YoY to Rs 157.11 crore in the quarter ended 31 March 2026. On a sequential basis, net profit increased 58.02% and revenue grew 27.27% over Q3 FY26. Profit before tax stood at Rs 31.67 crore in Q4 FY26, up 66.07% year-on-year and up 36.68% quarter-on-quarter. EBITDA jumped 50.38% to Rs 38.8 crore in the March quarter, compared with Rs 25.8 crore a year earlier. EBITDA margin improved to 24.6% from 22% in the corresponding period last year. For the full financial year FY26, the company reported a 69% surge in consolidated net profit to Rs 67.35 crore, while revenue from operations rose 35.89% to Rs 503.08 crore. Net cash used in operating activities stood at Rs 16.59 crore in FY26 compared with positive operating cash flow of Rs 52.72 crore in FY25. Kwality Pharmaceuticals is engaged in the business of manufacturing & trading in pharmaceuticals & allied products. Powered by Capital Market - Live News |